Insulin glargine
Key facts
Invented name |
Lantus
|
Active substance |
insulin glargine
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/133/2009
|
PIP number |
Insulin glargine
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Sanofi-Aventis Deutschland GmbH
E-mail: sylvie.gabriel@sanofi-aventis.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
Compliance procedure number |
EMEA-C-000387-PIP01-08
|
Compliance opinion date |
18/11/2011
|
Compliance outcome |
positive
|